Anvari and coworkers reported an association of high BCL2 expression with higher Gleason scores (GS) and lower biochemical recurrence-free survival in patients with advanced prostate cancer undergoing androgen deprivation therapy (ADT) [9]. Here, BCL2 is linked to Familial prostate cancer.